Better Buy: GlaxoSmithKline vs. Pfizer

Have all of the stocks of drugmakers in the coronavirus vaccine race delivered solid gains so far this year? Nope. GlaxoSmithKline's (NYSE: GSK) adjuvant is being used in three clinical-stage COVID-19 vaccine candidates, but its shares have plunged 20% year to date. Pfizer (NYSE: PFE) is arguably the clear leader in the race, but its shares are down around 7%.

The reason behind these declines is that both GlaxoSmithKline and Pfizer have a lot more going on than just their COVID-19 programs. Which of these stocks is the better choice for big-picture investors? Here's how GlaxoSmithKline and Pfizer compare on four key fronts.

Image source: Getty Images.

Continue reading

Source Fool.com